


08-20-04

IP! 1644



Attorney Docket No. 46943-CIP2 (71758)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Jin-an JIAO, et al.

U.S.S.N.: **09/990,586**

Group Art Unit: 1644

FILED: November 21, 2001

Examiner: M. Haddad

FOR: ANTIBODIES FOR INHIBITING BLOOD COAGULATION AND
METHODS OF USE THEREOF

.....
CERTIFICATE OF EXPRESS MAIL

I, Patricia A. Barnes, hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as "Express Mail Post Office To Addressee" service, **Label No. EV438994483US** in an envelope addressed to Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on **August 19, 2004**.

By: *Patricia A. Barnes*
Patricia A. Barnes

.....
**SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
(SUBMISSION AFTER FILING OF AN APPLICATION
BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE)**

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Date **August 19, 2004**

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

- a. ☒ Submitted herewith is a legible copy of (i) each U.S and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.

III. CONCISE EXPLANATION OF THE RELEVANCE
(check at least one box)

- a. ☒ Except as may be indicated below in (b), all of the patents, publications or other information are in the English language or were cited in an English language Search Report, a copy of which is attached hereto (concise explanation not required).
- b. ☐ A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:
- c. ☐ The following additional information is provided for the Examiner's consideration:

FEES

IV. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b)
(check one box)

- a. ☐ within three months of the filing date of a national application (37 C.F.R. § 1.97(b) (1)). No fee or certification is required.
- b. ☐ within three months of the date of entry of the national stage as set forth in §1.491 in an international application (37 C.F.R. § 1.97(b) (2)). No fee or certification is required.

- c. ☐ before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b) (3)). No fee or certification is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e) below, or, if no certification has been made, charge our deposit account a fee in the amount of \$1800.00 as required by 37 C.F.R. § 1.17(p).

V. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c):
(check one box)

before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c) (1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c) (2)).

- a. ☒ No certification; therefore, a fee in the amount of \$180.00 is required by 37 C.F.R. . § 1.17(p). A check in the amount of \$180.00 is enclosed.
or
b. ☐ See the certification below. No fee is required.

VI. CERTIFICATION UNDER 37 C.F.R. § 1.97(e) (check only one box)

The undersigned hereby certifies that

- a. ☐ each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- b. ☐ no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.
- c. ☐ Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned certifies that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was

known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

- ☐ Please charge Deposit Account No. 04-1105 in the amount of \$180.00 for the above-indicated fee. A triplicate copy of this paper is attached.
- ☐ No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition, if necessary) and charge the appropriate fee to Deposit Account No. 04-1105.

Respectfully submitted,


Date:

19 April 2004



Robert L. Buchanan, (Reg. No. 40,927)
EDWARDS & ANGELL, LLP
P. O. Box 55874
Boston, MA 02205
Tel: (617) 439-4444
Fax Nos.: (617) 439-4170 / 7748
Customer No.: 21874

#454792

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT			DOCKET NO: 46943-CIP2 (71758)	SERIAL NO.: 09/990,586
	APPLICANT(S): Jin-an JIAO, et al.			
	FILING DATE: November 21, 2001		GROUP NO.: 1644	

UNITED STATES PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	4,816,567	3/28/89	Cabilly et al.	530/387	435/68	4/8/83
	AB	5,122,458	6/16/92	Post et al.	435/69.1	435/69.2	1/11/89
	AC	5,168,062	12/1/92	Stinski	435/240.2	435/320.1	9/10/90
	AD	5,385,839	1/31/95	Stinski	435/240.2	435/69.1	6/17/92
	AE	5,879,677	3/9/99	del Zoppo	424/145.1	424/139.1	1/13/95
	AF	6,001,978	12/14/99	Edgington et al.	530/391.3	424/139.1	4/22/97
	AG	6,054,297	4/25/2000	Carter et al.	435/69.6	435/69.7	5/9/95
	AH	6,331,415 B1	12/18/01	Cabilly et al.	435/69.6	435/69.1	6/10/88
	AI	6,677,436 B1	1/13/04	Sato et al.	530/387.3	530/387.9	4/2/99
	AJ	2003/0119075 A1	6/26/03	Kirchhofer et al.	435/7.21	424/145.1	3/8/01
	AK	2003/0087372 A1	5/8/03	DelaCruz et al.	435/69.1	435/325	6/11/02
	AL	5,889,157	3/30/99	Pastan et al.	530/387.1	530/387.3	10/28/94
	AM	6,610,293 B1	8/26/03	Fischer et al.	424/133.1	530/387.3	6/15/98
	AN	5,530,101	6/25/96	Queen et al.	530/387.3	530/387.1	12/19/90

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO
	BA	EP 1 069 185 A1	17/01/2001	Europe			Y

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

CA	I. Benhar, et al., Rapid Humanization of the Fv of Monoclonal Antibody B3 By Using Framework Exchange of the Recombinant Immunotoxin B3(Fv)-PE38, Proc. Natl. Acad. Sci. USA, December 1994, Vol. 91, pages 12051-12055.
CB	J. R. Couto, et al., Anti-BA46 Monoclonal Antibody Mc3: Humanization Using a Novel Positional Consensus and in Vivo and in Vitro Characterization, Cancer Research, April 15, 1995, Vol. 55, pages 1717-1722.

#454800